Paradigm Biopharma osteoarthritis trial recruitment ‘ahead of schedule’

Paradigm Biopharma (ASX: PAR) has recruited more than 80% of its patients needed for its phase 2b osteoarthritis and concurrent bone marrow lesion clinical trial, with results anticipated “ahead of schedule” in the December quarter of this year. The company expects recruitment will be finished this month with the six treatment sites currently operational. As … Continue reading Paradigm Biopharma osteoarthritis trial recruitment ‘ahead of schedule’